Compare Amphastar Pharmaceuticals Inc (AMPH) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Gartner Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Gartner Inc trades at $136.09 (market cap $8.92B). The key difference: Gartner Inc is far larger — about 10.8× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | IT | |
|---|---|---|
Market Cap | $826.08M | $8.92B |
Sector | Health | Technology |
52-Week High | $30.81 | $374.40 |
52-Week Low | $16.87 | $125.68 |
Enterprise Value | $1.22B | $10.51B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Gartner (IT) trades at $133.24, up 0.41% today, with a bearish technical signal but strong recent earnings beats. The company shows robust profitability with a 68.99% gross margin and 11.44% net margin, though 2025 net income declined to $729M from $1.3B in 2024. Analyst consensus is mixed with a $157.60 price target, while news highlights ongoing investigations and industry events.
Outlook is cautious due to technical bearishness and net cash outflows, but valuation appears reasonable with a P/E of 13.17. Risks include competitive pressures and the recent legal investigation. Upside potential exists if earnings momentum continues and sentiment improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
